Gateway Investment Advisers LLC Buys 5,431 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Gateway Investment Advisers LLC increased its holdings in Gilead Sciences by 7.7% during 2Q, owning 75,651 shares valued at approximately $8.39 million.
• Several major investors, including Price T Rowe Associates and Vanguard Group, significantly boosted their positions in Gilead, with institutional investors now holding 83.67% of the stock.
• A quarterly dividend of $0.79 per share has been announced, with an expected annual yield of 2.8%, effective from September 29th.

Gateway Investment Advisers LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 75,651 shares of the biopharmaceutical company's stock after buying an additional 5,431 shares during the period. Gateway Investment Advisers LLC's holdings in Gilead Sciences were worth $8,387,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Argentarii LLC grew its position in Gilead Sciences by 3.0% during the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock valued at $380,000 after buying an additional 99 shares during the period. Peak Financial Advisors LLC lifted its stake in Gilead Sciences by 1.7% in the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock valued at $677,000 after purchasing an additional 100 shares during the last quarter. Perkins Coie Trust Co increased its position in Gilead Sciences by 2.6% in the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock worth $435,000 after buying an additional 100 shares during the last quarter. Investment Research & Advisory Group Inc. raised its stake in shares of Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 100 shares during the period. Finally, Lodestar Private Asset Management LLC lifted its position in shares of Gilead Sciences by 3.6% during the 1st quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company's stock valued at $318,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares of the company's stock, valued at $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider directly owned 113,193 shares in the company, valued at $12,855,329.01. This trade represents a 2.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock valued at $9,390,030 over the last ninety days. Insiders own 0.27% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded up $0.47 during mid-day trading on Friday, reaching $114.09. 12,580,487 shares of the company were exchanged, compared to its average volume of 8,095,334. Gilead Sciences, Inc. has a 52 week low of $81.83 and a 52 week high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $141.56 billion, a PE ratio of 22.73, a PEG ratio of 0.76 and a beta of 0.36. The company's 50 day moving average price is $114.01 and its 200 day moving average price is $110.07.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm's revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio is presently 62.95%.

Analyst Ratings Changes

A number of research analysts have recently commented on GILD shares. Royal Bank Of Canada upped their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research report on Friday, August 8th. Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price objective for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective for the company in a research note on Tuesday, August 19th. Finally, Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.